Mainz Biomed Stock Surges 12% After Q1 Progress Update And FDA Approval Pathway News

(RTTNews) - Mainz Biomed N.V. (MYNZ) jumped 12.69 percent to $3.98, rising $0.45 during Monday's trading, after the company highlighted significant milestones achieved in the first quarter of 2025 and provided updates on its path toward FDA premarket approval for its next-generation colorectal cancer screening test.

Shares opened at $3.9700 and traded between $3.5700 and $4.4299 during the session on the Nasdaq. Volume soared to 1.73 million shares compared to an average of 218,691. Mainz Biomed trades within a 52-week range of $0.1800 to $8.2000.

Key developments included enrolling the first patient in the eAArly DETECT 2 study, launching ColoAlert in Switzerland through a new partnership, and regaining full Nasdaq listing compliance.